Financial forecasting platforms and equity analysts tracking Fulgent Genetics (NASDAQ: FLGT) project moderate valuation ranges for the equity. Consensus target estimates from available analyst coverage place predictions around the $19.00 range, though algorithmic forecasting models vary depending on assumptions regarding core clinical testing volume growth, cash reserves utilization, and diagnostic market competition over upcoming fiscal quarters.